The $100M biotech club: Who's in, and what’s it take to join the top-per­form­ing group of bio­phar­mas?

7 years ago
Pharma

As drug­mak­ers seek ways to elude IL-2 flaws, Clin­i­gen se­cures the full rights to orig­i­nal trou­bled IL-2 drug ...

7 years ago
Pharma

Affini­vax, Astel­las be­gin clin­i­cal quest to beat Pfiz­er's Go­liath with a new kind of pneu­mo­coc­cal vac­cine

7 years ago
R&D

House com­mit­tee weighs drug pric­ing pro­pos­als

7 years ago
Pharma

FDA ex­perts of­fer a big thumbs up for J&J’s flawed ap­pli­ca­tion for ke­t­a­mine-based de­pres­sion drug — but tri­al ...

7 years ago
Pharma

Chi­na vows to con­tin­ue speed­ing up drug ap­provals, ex­pand tax cuts; Sor­ren­to/Yuhan JV re­ceives $40M fi­nanc­ing

7 years ago
News Briefing

The high rollers: The top 20 block­buster bio­phar­ma deals of the past decade

7 years ago
Pharma

In the bat­tle against kid­ney can­cer, Mer­ck­'s key­stone im­munother­a­py Keytru­da edges in front

7 years ago
R&D

Hill­house Cap­i­tal en­dors­es Chi­na-based Hai­He Bio­phar­ma's can­cer pipeline in $146M round

7 years ago
Financing
China

As dig­i­tal med­i­cine ex­plodes in the zeit­geist of health­care, Sanofi fol­lows peers in ap­point­ing chief dig­i­tal of­fi­cer

7 years ago
People

Af­ter a short stint at In­ter­cept, Rachel McMinn makes the leap from biotech an­a­lyst to biotech CEO

7 years ago
People
Financing

FDA tar­gets prod­ucts false­ly claim­ing to treat Alzheimer’s dis­ease

7 years ago
Pharma

It's a flop: Gilead­'s top late-stage drug selon­sert­ib flunked its first Phase III NASH tri­al

7 years ago
R&D

David Schenkein gets his third act in biotech, join­ing Google's GV to co-lead life sci­ences group

7 years ago
People

3SBio inks Chi­na deal with Boston-based Verseau; Er­ic Topol calls for dig­i­tal ed­u­ca­tion in NHS re­port

7 years ago
News Briefing

FDA promis­es speedy re­view on mov­ing Mer­ck­'s Keytru­da up as first-line head and neck can­cer ther­a­py

7 years ago
Pharma

Top 20 biotech deals: 2019 deal­mak­ing gets off to a roar­ing start, build­ing on a record amount for '18

7 years ago
Pharma

Cure­Vac walks away from Arc­turus' urea cy­cle dis­or­der drug, but part­ner­ship re­mains in­tact

7 years ago
R&D

Ab­b­Vie jumps in­to the fren­zied race for a BC­MA/CD3 bis­pe­cif­ic tar­get­ing mul­ti­ple myelo­ma. Teneo­bio who?

7 years ago
Pharma

So­lid­i­fy­ing a new cor­po­rate struc­ture, IFM launch­es sec­ond unit fo­cused on cGAS-STING

7 years ago
Startups

Re­gen­eron, Sanofi slash Pralu­ent list price mir­ror­ing Repatha dis­count

7 years ago
Pharma

Canaan leaps in­to UK biotech by co-lead­ing $14M Se­ries A for im­muno-on­col­o­gy up­start Grey Wolf

7 years ago
Financing
Startups

As­traZeneca CEO So­ri­ot is over­see­ing a top ex­ec team over­haul in move to in­te­grate Med­Im­mune in a sweep­ing ...

7 years ago
People

Macro­mol­e­cules in a pill? Tor­toise-in­spired cap­sule of­fers hope in an ear­ly test de­liv­er­ing in­sulin in­to stom­ach wall

7 years ago
Pharma
First page Previous page 960961962963964965966 Next page Last page
A service from the Financial Times